Class II
Ongoing
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591;…
Why: Lack of Assurance of Sterility
- Company
- Regeneron Pharmaceuticals Inc
Tarrytown, NY, United States - Reported
- Aug 26, 2026
- Recall started
- Jul 28, 2026
- Where sold
- USA Nationwide
- Amount
- 21,353 vials
- Full product description
- Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01
- Lots / codes affected
- Lot: 8494000002, Exp 7/31/28
Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.